Local challenge on oral mucosa with an α-gliadin related synthetic peptide in patients with celiac disease

OBJECTIVE:Gluten-derived peptides (e.g., amino-acids 31–49 of α-gliadin) have been shown to cause changes typical of celiac disease in the gut. Gluten-derived peptides have mostly been used in in vitro studies. The easiest access to the gastrointestinal system may be the mouth. In the present study we were interested to see whether a synthetic peptide corresponding to amino-acids 31–49 of α-gliadin could induce inflammatory changes in the oral mucosa after a local challenge in celiac disease patients.METHODS:The challenge was made by injecting the peptide solution at a concentration of 10 μg/ml submucosally into the oral mucosa of 10 celiac disease patients after a gluten-free diet (GFD) and 12 healthy control subjects. B and CD45RO+ T cells, mast cells, CD3+, CD4+, CD8+ lymphocytes, and αβ and γδ T-cell receptor-bearing (TcRαβ, TcRγδ) lymphocytes were counted and HLA DR expression was determined. The expression of CD25 and Ki-67 antigen was also examined.RESULTS:The peptide significantly increased the total number of T cells in the lamina propria of the celiac disease patients. The expression of T-cell activation marker CD25 (IL-2 receptor), but not that of cell proliferation marker Ki-67, was also significantly increased in the lamina propria after peptide challenge. Such a reaction was not observed in the controls. The numbers of CD3+ and CD4+ T cells in the lamina propria were also increased in celiac disease patients after the challenge. The count of TcRγδ+ cells was very small in the oral mucosa in celiac disease and showed no increase when the oral mucosa was challenged with the peptide. The expression of HLA DR staining was enhanced after the submucosal peptide challenge in celiac disease; however, the difference was not statistically significant.CONCLUSIONS:The results show that in the celiac disease patients after the peptide challenge the oral mucosal lamina propria responds with a nonproliferative increase of lymphocytes. Thus, submucosal challenge with the peptide 31–49 can be used as an aid in the diagnosis of celiac disease. However, further studies with optimized methodology, including various concentrations of the peptide, adjuvants, other peptides, etc., are warranted, especially because the oral mucosa provides the easiest access to an in vivo peptide challenge in celiac disease.

[1]  Fernando Gomollón.  Celiac sprue. , 2002, The New England journal of medicine.

[2]  M. Mäki,et al.  Local challenge of oral mucosa with gliadin in patients with coeliac disease , 2000, Clinical and Experimental Immunology.

[3]  N. Brousse,et al.  Gluten-free diet induces regression of T-Cell activation in the rectal mucosa of patients with celiac disease , 1998, American Journal of Gastroenterology.

[4]  F. Koning,et al.  Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. , 1998, Journal of immunology.

[5]  L. Fugger,et al.  Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease , 1998, Nature Medicine.

[6]  D. Green,et al.  Fas ligand- mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. , 1998, The Journal of clinical investigation.

[7]  D. Schuppan,et al.  Identification of tissue transglutaminase as the autoantigen of celiac disease , 1997, Nature Medicine.

[8]  M. Mäki,et al.  Intraepithelial lymphocytes bearing the γ/δ receptor in the oral and jejunal mucosa in patients with dermatitis herpetiformis , 1997 .

[9]  T. Macdonald,et al.  A major role for matrix metalloproteinases in T cell injury in the gut. , 1997, Journal of immunology.

[10]  T. Reunala,et al.  Intraepithelial lymphocytes bearing the gamma/delta receptor in the oral and jejunal mucosa in patients with dermatitis herpetiformis. , 1997, European journal of oral sciences.

[11]  L. Maiuri,et al.  In vitro activities of A-gliadin-related synthetic peptides: damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa. , 1996, Scandinavian journal of gastroenterology.

[12]  G. A. Limb,et al.  Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge. , 1995, Gut.

[13]  H. Wieser.  The precipitating factor in coeliac disease. , 1995, Bailliere's clinical gastroenterology.

[14]  K. Lundin,et al.  Wheat peptide challenge in coeliac disease , 1994, The Lancet.

[15]  K. Sletten,et al.  In Vitro Toxicity of Purified Gluten Peptides Tested by Organ Culture , 1994, Journal of pediatric gastroenterology and nutrition.

[16]  E. Thorsby,et al.  Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients , 1993, The Journal of experimental medicine.

[17]  T. Halstensen,et al.  Activated T lymphocytes in the celiac lesion: Non‐proliferative activation (CD25) of CD4+ α/β cells in the lamina propria but proliferation (Ki‐67) of α/β and γ/δ cells in the epithelium , 1993, European journal of immunology.

[18]  E. J. Lew,et al.  In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease. , 1988, Gastroenterology.

[19]  H. Wieser,et al.  Coeliac activity of the gliadin peptides CT-1 and CT-2 , 1986, Zeitschrift fur Lebensmittel-Untersuchung und -Forschung.

[20]  T. Okita,et al.  Nucleic acid (cDNA) and amino acid sequences of alpha-type gliadins from wheat (Triticum aestivum). , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Aksnes,et al.  Morphological and morphometric assessment of human duodenal biopsies maintained in organ culture. In vitro influences of gluten in coeliac disease. , 1981, Scandinavian journal of gastroenterology.